- 1 Remedial dosing recommendation for delayed or missed rivaroxaban doses for
- 2 patients with non-valvular atrial fibrillation based on Monte Carlo simulation
- 3 Xiao-qin Liu^{1,2}, Yi-wei Yin¹, Chen-yu Wang¹, Zi-ran Li^{1,2}, Xiao Zhu³, Zheng Jiao^{1*}
- 4 Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University,
- 5 Shanghai, China

10

- 6 ² Department of pharmacy, Huashan Hospital, Fudan University, Shanghai, China
- ³ School of Pharmacy, University of Otago, Dunedin, New Zealand
- 9 Xiao-qin Liu and Yi-wei Yin contributed equally to this work.
- 11 *Corresponding author:
- 12 Zheng Jiao, Professor
- 13 Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University
- 14 241 Huaihai West Road, Shanghai, China, 200030
- 15 Tel.: +86 (21) 2220 0000
- 16 E-mail: jiaozhen@online.sh.cn
- 17 ORCID: 0000-0001-7999-7162

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

Abstract **Background** Rivaroxaban is a non-vitamin K oral anticoagulant used widely for stroke prevention in patients with non-valvular atrial fibrillation (NVAF). During long-term anticoagulant therapy, delayed or missed doses are common. However, a lack of practical instructions on remedial methods has created a barrier for patients to maximise the benefit of their medications. This study aimed to explore appropriate remedial dosing regimens for rivaroxaban-treated patients with NVAF. Methods Monte Carlo simulation based on a previously established rivaroxaban population pharmacokinetic/pharmacodynamic model for patients with NVAF was employed to design remedial dosing regimens. Both the European Heart Rhythm Association (EHRA) recommendations and the model were used to establish remedial dosing regimens, which were assessed considering the on-therapy range of drug concentration, factor Xa activity, and prothrombin time under various scenarios of non-adherence. Results Recommendations of EHRA guide may not be optimal. Our findings suggested that a missed dose is taken immediately when the delay is less than or equal to 6 h; a half dose is advisable when the delay exceeds 6 h but is less than 4 h before the next dose. It is recommended to skip a dose when there are less than 4 h before the next dose. Age or renal function do not significantly influence the remedial dosing regimen.

38 Conclusion A remedial dosing regimen based on model-based Monte Carlo

simulation was systematically developed for rivaroxaban-treated patients with NVAF

with poor adherence to quickly restore drug concentrations to the on-therapy range

and to reduce the risk of bleeding and thromboembolism.

39

40

42 Key words: anticoagulation, rivaroxaban, non-adherence, Monte Carlo simulation,

43 population pharmacokinetics and pharmacodynamics

What is known on this topic?

- Remedial recommendations for delayed or missed rivaroxaban dose have been mentioned in package inserts and guide, but lack of solid supporting evidence.
- Monte Carlo simulation based on population analysis have been proved as an appropriate method to explore the remedial dosing strategy.

What does this paper add?

- Remedial recommendations for delayed or missed rivaroxaban in different population are established based on Monte Carlo simulation.
- The choice of optimal remedial strategy is related to delay duration.
- This paper provides a more time-specific and individualized recommendations compared with previous recommendations.

1 Introduction

1

2 Rivaroxaban is one of the most commonly used non-vitamin K oral anticoagulants 3 (NOACs), and was the first oral direct factor $\Box a$ (F $\Box a$) inhibitor approved for stroke prevention in patients with non-valvular atrial fibrillation (NVAF) 1-5. More than 4 5 two-thirds of rivaroxaban doses are excreted by the kidney as metabolites or unchanged drugs ^{6,7}: therefore, dose adjustment based on renal function is required in 6 patients with moderate renal impairment (creatinine clearance, CrCl, 30–49 mL/min)² 7 8 to achieve consistent efficacy and safety, when compared with the case in individuals 9 with normal renal function ⁸. 10 Patients with NVAF receiving anticoagulant therapy usually require long-term 11 therapy; however, adherence to NOACs, including rivaroxaban, decreases over time. 12 In a large retrospective study, adherence to rivaroxaban was 68% 3 months after 13 treatment initiation, and decreased to 50% after 12 months of treatment ⁹. Additionally, a considerable proportion of NVAF patients are elderly (> 70 years) ^{10,11}. 14 15 Delayed or missed doses, which represent a major form of non-adherence in clinical practice, is common in this population of elderly patients ^{12,13}. As a class of drugs 16 with fast on/fast off characteristics ¹⁴, non-adherence is associated with an increasing 17 risk of thromboembolic events ¹⁵. For example, a 10% decrease in dabigatran 18 19 adherence, another NOAC, results in a 13% increase in all-cause mortality and stroke ¹⁶. Therefore, appropriate remedial dosing for patients with poor adherence is 20

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

necessary to minimise the occurrence of thromboembolic events. Developing an appropriate remedial regimen is essential for the prevention of overdose-related bleeding events and underdose-related thromboembolic events caused by inappropriate remedial dosing. By providing scenario-specific instructions, patients can maximise the benefit and minimise the risk associated with rivaroxaban therapy. Several resources provide recommendations for patients who experience a delayed or missed dose. The package inserts from the United States Food and Drug Administration (US FDA) states that 'the patient should take the missed rivaroxaban dose immediately. The dose should not be doubled within the same day to make up for a missed dose' ². Similar recommendations are found in patient information leaflets ¹⁷ and consumer medicine information ¹⁸. Furthermore, the 2018 European Heart Rhythm Association (EHRA) practical guide on the use of non-vitamin K antagonist oral anticoagulant in patients with atrial fibrillation recommends that 'for NOACs with a once-a-day dosing regimen, a delayed dose can be taken up until 12 h after the scheduled intake. After this time point, the dose should be skipped, and the next scheduled dose should be taken' 19. However, these recommendations are not supported by solid evidence from clinical studies or by extrapolation from pharmacokinetic/pharmacodynamic (PK/PD) analyses. It is also uncertain whether the recommendation can be applied to patients with impaired renal function. Although human studies are ideal for assessing proposed remedial regimen, prospective clinical research is unethical, and post-marketing adherence data are

appropriate remedial doses ²⁰. Monte Carlo simulations based on established population PK/PD models provide a practical approach to overcome this problem and have been successfully applied to antiepileptic, antipsychotic, and immunosuppressive agents ²¹. Therefore, this study aimed to (i) assess the effect of delayed dose on the PK/PD of rivaroxaban and (ii) explore appropriate remedial dosing regimens by Monte Carlo simulation for patients with NVAF receiving rivaroxaban.

2 Materials and methods

2.1 Patients and dosing regimen

Adult patients (aged 55 or 75 years old) with various levels of creatinine clearance (CrCl, calculated by the Cockcroft-Gault formula ²²) were simulated, including patients with normal and moderately impaired renal function (CrCl 80 and 40 mL/min, respectively). The demographic characteristics of patients with NVAF were collected from epidemiologic reports ^{10,11,23}. As indicated on the US FDA label ² and as recommended in the 2018 EHRA guide ¹⁹, patients with CrCl ≥50 mL/min received rivaroxaban 20 mg every 24 h (q24h), and those with CrCl 30–49 mL/min received 15 mg q24h. It was assumed that patients take rivaroxaban with food at the same time every day. Demographic information and simulated dosing regimens for typical patients are listed in Table 1.

2.2 Remedial dosing regimen assessment

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

For patients with NVAF taking rivaroxaban 20 or 15 mg daily, various scenarios were investigated in which doses were delayed from 1 to 24 h after the scheduled time (Figure 1). 2.2.1 Population PK/PD model and simulation A previously published population PK/PD analysis of rivaroxaban was used in our study ²⁴. The study cohorts were obtained from a subset of patients in the largest multinational phase III ROCKET AF trial (Rivaroxaban once daily Oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) ²⁵. A total of 161 patients with NVAF, with time-matched PK and PD samples were included in this population PK/PD analysis. These included 136 patients with normal or mildly impaired renal function (CrCl≥50 mL/min) receiving 20 mg daily, and 25 patients with moderate renal impairment (CrCl 30-49 mL/min) receiving 15 mg daily. Detailed demographic and dosing regimen information is listed in Supplementary Table 1. Blood samples were used to determine rivaroxaban concentration, Factor Xa (FXa) activity, and prothrombin time (PT). In this analysis, population PK was depicted by a one-compartment model with first-order absorption and elimination. The PK model was parameterised by the absorption rate constant (k_a), apparent clearance (CL/F), and apparent volume of distribution (V/F). The time-concentration relationship is described in Eq. 1.

$$C_p = \frac{k_a \cdot F \cdot DOSE}{V \cdot (k_a - \frac{CL}{V})} \cdot \left[\left(\frac{1 - e^{-\frac{CL}{V} \cdot n \cdot \tau}}{1 - e^{-\frac{CL}{V} \cdot \tau}} \cdot e^{-\frac{CL}{V} \cdot t} \right) - \left(\frac{1 - e^{-k_a \cdot n \cdot \tau}}{1 - e^{-k_a \cdot \tau}} \cdot e^{k_a \cdot t} \right) \right] \ (Eq.1)$$

- This equation comprised bioavailability (F), dose (DOSE; mg), apparent volume of
- distribution (V; L), number of doses administered (n), dosing interval (τ ; h), time after
- 85 the last dose (t; h), and concentration at time t (C_p; mg/L). Age and serum creatinine
- 86 (SCr; mg/dL) affected CL/F (Eq 2.), while age and lean body mass (LBM) influenced
- 87 V/F (Eq 3.).

88
$$CL/F(L/h) = 6.1 \times (1-0.011 \times [age-65]-0.194 \times [SCr - 1.09])$$
 (Eq. 2)

89
$$V/F(L) = 79.7 \times (1-0.00133 \times [age-65] + 0.0118 \times (LBM - 57.5])$$
 (Eq. 3)

- 90 PD markers, including FXa activity and PT, were modelled to correlate with
- 91 rivaroxaban concentration. FXa activity was negatively correlated with the
- 92 concentration of rivaroxaban, with a direct inhibitory maximum-effect (E_{max})
- 93 relationship, as described by Eq 4.

94 FXa =
$$E_0 \times (1 - \frac{E_{\text{max}} \times C_p}{EC_{50} + C_p})$$
 (Eq.4)

- 95 where, E₀ represents baseline FXa activity, E_{max} represents the relative maximum
- 96 level of inhibition, and EC₅₀ represents the concentration of rivaroxaban resulting in
- 97 50% of maximum inhibition.
- 98 PT was positively correlated with rivaroxaban concentration in a near-linear
- 99 relationship, as described by Eq 5.

100
$$PT = PT_0 + slope \cdot C_p^{1-exponent \cdot C_p}$$
 (Eq.5)

101 PT₀ represents baseline PT, slope represents the per unit difference in CrCl (mL/min) 102 to the median CrCl (76 mL/min), and the exponent represents the parameter 103 describing the decline linearly with increasing C_p . CrCl was found to affect both PT_0 104 and the exponent, which is expressed by Eq.6 and Eq.7. 105 $PT_0=11.4\cdot(1-0.000192\cdot[CrCl-76])$ (Eq.6) 106 Exponent= $0.0000551 \cdot (1+0.0174 \cdot [CrCl-76])$ (Eq.7)107 All PK/PD parameter estimates employed in the Monte Carlo simulation are listed in 108 Table 2. 109 Monte Carlo simulations were performed with NONMEM software (version 7.4; Icon 110 Incorporation, PA, USA) using the \$SIMULATION block. Output profiles were 111 processed using the R package (version 3.5.3, https://www.r-project.org/). A total of 112 5000 virtual patients were simulated to depict the PK/PD profiles under each 113 non-adherence scenario. Virtual patients were assumed to have already received 114 multiple doses of rivaroxaban and have reached steady state, and to obtain the 115 expected level of anticoagulation without any unexpected drug-related adverse 116 effects. 117 2.2.2 Remedial dosing regimens Based on previous research and on clinical practise ²¹, six strategies, as well as 118 119 recommendations included in the EHRA guide, assessed when the dose was delayed

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

or missed. Graphic remedial strategies are shown in Figure 2, and details are below as follows: Strategy A: skip the delayed dose, administer the regular dose at the next scheduled dosing time, and then resume the regular dosing regimen. Strategy B: administer the regular dose immediately, followed by a regular dose at the next scheduled dosing time, and then resume the regular dosing regimen. Strategy C: administer a half dose immediately followed by a regular dose at the next scheduled dosing time, and then resume the regular dosing regimen. Strategy D: administer a regular dose immediately followed by a half dose at the next scheduled dosing time, and then resume the regular dosing regimen. Strategy E: administer one and a half regular doses immediately, skip the next scheduled dose, and then resume the regular dosing regimen. Strategy F: administer a double dose, skip a dose at the next scheduled dosing time, and then resume the regular dosing regimen; EHRA guide: administer the delayed dose if less than 12 h late; otherwise, skip the delayed or missed dose and administer the next scheduled dose. 2.2.3 Index for evaluating remedial regimens Currently, there is no widely accepted therapeutic range of rivaroxaban concentrations, FXa activity, or PT. Therefore, the on-therapy range, defined as the 'interval delineated by the 5th percentile trough concentration and the 95th percentile peak

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

concentration' at the steady state of a given dose ^{26,27}, was used in this study. Considering the differences in patient demographics, we estimated the on-therapy range for each typical patient at steady state by Monte Carlo simulation. To assess the effect of a delayed or missed dose, we defined the percentage of individuals outside the on-therapy range as those whose concentration or PD marker levels were not within the on-therapy range. The percentages of individuals outside the on-therapy range under all non-adherence scenarios described above were estimated to evaluate the effect of non-adherence over time. Deviation time, defined as the duration when simulated rivaroxaban concentration, FXa activity or PT are outside the on-therapy range, was chosen as the index to evaluate the remedial regimen. It was calculated by adding each deviation time when simulated data is higher than the upper limit and lower than the lower limit of on-therapy range. The two aspects of deviation time may represent higher risk of bleeding and thromboembolic events, respectively. It was assumed that patients taking regular rivaroxaban doses had reached expected anticoagulant effects within the on-therapy range. Therefore, when the rivaroxaban dose was delayed or missed, optimal remedial dosing could help patients to restore the rivaroxaban concentration, FXa, or PT to the on-therapy range as soon as possible to minimise the deviation time. Two remedial dosing regimens with deviation times of less than 1 h were assumed to be equivalent. If there were discrepancies among recommendations for rivaroxaban concentration, FXa activity, or PT, those based on FXa activity were prioritised. This

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

was because quantification of FXa activity is considered as a more specific biomarker for NOACs, which is recommended by the International Society on Thrombosis and Haemostasis American College of Chest Physicians guidelines ^{28,29}. 2.2.4 Sensitivity analysis A sensitivity analysis was applied to identify parameters that had a substantial influence on model output, and to determine the extent that these important parameters contributed to the overall variability in model output ³⁰. Therefore, dosing intervals and demographic characteristics (age and body weight) were included in the sensitivity analysis to investigate their influence on the remedial dosing regimens. Irregular dosing intervals of 23-25 h (18:00, 17:00, and 18:00) and 25-23 h (18:00, 19:00, and 18:00) were assessed considering situations where patients took rivaroxaban at different times every day. Moreover, considering the demographics of the modelling population, patients with different ages and body weights (expressed as LBM in population analysis) were also investigated (Supplementary Table 2). Furthermore, the criterion used to judge the equality of the two strategies was also examined from 0.5 to 2 h, to investigate whether it had an influence on the remedial dosing recommendations. 3 Results 3.1 Effect of delayed or missed doses of rivaroxaban on PK/PD

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

The results from the Monte Carlo simulation showed that the effect of a delayed dose was related to the delay time. With an increasing delay time, the risk of a patient being outside the on-therapy range was also increased considering both the PK and PD (Figure 3). For example, among patients with CrCl of 80 mL/min who took rivaroxaban 20 mg q24h, 12.6% and 47.9% patients were outside the on-therapy range based on rivaroxaban concentration when the dose was delayed for 6 h and 24 h, respectively. The effect of delayed dose was not significantly affected by age or renal function. (Figure 3). For example, among elderly patients with normal renal function and impaired renal function, the percentage of those who were outside the on-therapy concentration range was 22.6% and 20.4% when the dose was delayed for 12 h, respectively, representing a difference less than 15%. Moreover, the difference in the percentages of patients who were outside of the FXa activity (8.6 vs. 8.26%) or PT on-therapy (10.2 vs. 10.1%) range were also less than 15%. In addition, the impact of the delayed dose on the PK/PD was very similar when the delay time was less than 3 h. However, the difference increased as the delay time increased (Figure 3). Considering rivaroxaban concentration, this percentage increased approximately linearly with time. The percentage changes considering FXa activity and PT were close, with a smaller slope and increased with the delay time. For example, for adult patients receiving a 20 mg q24h dose delayed for 2 h, the percentages of those outside the on-therapy range were 6.9, 6.5, and 6.4% for

rivaroxaban concentration, FXa activity, and PT, respectively. These percentages were 23.4, 7.6, and 9.3%, respectively, when dosing was delayed for 12 h, with a greater difference between rivaroxaban concentration and PD markers compared with that at 2 h.

3.2 Remedial dosing regimens

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

The remedial dosing recommendations following a delayed rivaroxaban dose are summarised in Table 3. Figure 4a-c shows the concentration, FXa activity, and PT profiles for fully adherent elderly patients with impaired renal function (aged 75 years, CrCl 40 mL/min, receiving 15 mg q24h). In general, remedial dosing recommendations are related to delayed time. A regular dose of rivaroxaban could be taken immediately when the delay doesn't exceed 6 h. When the delay exceeds 6 h but is less than 20 h, it is advisable to remedy a half dose either by taking a half dose immediately followed by a regular dose at the next scheduled time (6–14 h), or by taking a regular dose immediately followed by a half dose at the next scheduled dosing time (14-20 h). When the delay exceeds 20 h, it is recommended to skip the delayed dose and take a regular dose at the next scheduled dosing time. When a dose is missed, it is advisable to take a regular dose at the scheduled dosing time. Recommendations based on rivaroxaban concentration and FXa or PT levels were the same among almost all scenarios, except for scenarios where the delay time was 3–6 h. Rivaroxaban concentration, FXa activity, and PT profiles following a delay of 6 h

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

under optimal remedial regimens for elderly patients with impaired renal function (aged 75 years, CrCl 40 mL/min, taking 15 mg q24h) are shown in Figure 4d-f. Under this scenario, recommendations based on FXa activity supported taking a regular dose immediately, while recommendations based on concentration and PT preferred taking a half dose. Based on pre-established criteria where FXa activity was preferred, recommendations based on FXa activity were selected. Additionally, age and renal function did not affect remedial dosing regimens. For example, for adult patients with normal renal function, a half dose (10 mg) is recommended when the dose is delayed by 6-20 h, based on rivaroxaban concentration, FXa activity, and PT. For elderly patients with impaired renal function taking a lower daily dose, a half dose (7.5 mg) is also recommended when the delay was 6–20 h. Because recommendations from the EHRA did not consider splitting rivaroxaban tablets, this represented a missed opportunity to provide a more personalised remedial strategy. Based on the present results, our recommendation is consistent with that of the EHRA only when the delay was less than 3 h, or it was less than 4 h before the next dose. Recommendations from the EHRA guide are not optimised for most scenarios. A comparison of the deviation time between the EHRA guide and our proposed remedial strategy is shown in Figure 5. Deviation times under different strategies are listed in Supplementary Table 3-6, which can provide supportive information to balance the risk of thromboembolism and bleeding.

3.3 Sensitivity analysis

Age, body weight, dosing intervals, and criterion for assessing the equality of the two strategies were included in the sensitivity analysis when the rivaroxaban dose was delayed for 3, 6, 12, and 24 h. Deviation time may vary slightly by age, body weight, and dosing intervals. However, these factors did not significantly impact remedial dosing regimens (Supplementary Figure 1). Broadening the criterion for assessing the equality of the two strategies resulted in more options for remedial strategies at some time points, whereas narrowing the criterion resulted in fewer options (Supplementary Tables 7–10). As shown in Table 3, for adult patients with normal renal function, recommendations included 10 mg with strategy C or 20 mg with strategy B when there was a delay of 4 h considering the PT. However, the recommended strategy only included 10 mg with strategy C when the criteria were narrowed. When the criteria were broadened, 10 mg with strategy D was included in the recommended strategies.

4 Discussion

This was the first study to characterise the effects of delayed rivaroxaban dose on the PK/PD profiles and to investigate appropriate remedial dosing regimens for patients with NVAF under different scenarios. A few studies have estimated the rate of non-adherence of NOACs and explored the associated risk factors ^{12,13,15}. However, non-adherence is common, and very few studies have proposed solutions when doses are delayed or missed. Considering the high risk for thromboembolism resulting from

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

non-adherence and the serious consequences resulting from inappropriate remedial and missing/delayed doses, our study is the first to provide insight into remedial regimens for patients with NVAF following delayed or missed rivaroxaban doses. Our study explored optimal remedial regimens based on Monte Carlo simulation from the perspective of both PK and PD, and considering both population level and individual variation. Handling delayed doses from the population PK perspective has been previously discussed for various diseases, such as epilepsy³¹⁻³⁴, schizophrenia ^{35,36} and renal transplantation ³⁷. However, few studies have explored this with consideration of PD, or PK/PD ²¹. The PD effect should also be considered for medicine acting via an indirect mechanism ³⁸, such as rivaroxaban, which acts as an indirect anticoagulant by inhibiting FXa activity. Multiple PK and PD markers were used in our study, including rivaroxaban concentration, FXa activity, and PT. Given that no clearly defined therapeutic ranges have been established for rivaroxaban ²⁶, an on-therapy range was adopted to describe appropriate maintained levels of concentration, FXa activity, and PT. The concept of an on-therapy range has been used for antiepileptic drugs, and was thought to be appropriate for epilepsy management ^{32,33}. Regarding rivaroxaban, the calculated PK on-therapy ranges based on simulated data are close to those estimated in clinical trials ³⁹. We hypothesised that patients taking the prescribed dose could obtain expected anticoagulation outcomes within the on-therapy range. It is reasonable to assume that a remedial strategy restoring drug concentrations to a previous range can

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

minimise negative outcomes associated with non-adherence, such as lower exposure, in addition to potential thromboembolic events. Through population analysis and Monte Carlo simulation, our study provides remedial dosing recommendations that are more time-specific than those included in the EHRA guide. Recommendations from the EHRA are general for all NOACs, including rivaroxaban, apixaban, edoxaban, and dabigatran ¹⁹. Our research optimises these recommendations from both PK and PD perspectives, suggesting that the cut-off point for remedying a full dose is not 12 h, as noted in the EHRA guide. Based on the concentration and PT, the cut-off point is approximately 3 h, while based on FXa activity, the cut-off is approximately 6 h. When the dose is delayed for less than the cut-off point, taking the delayed dose of rivaroxaban as soon as possible is recommended. However, when the delay exceeds the cut-off point, a half dose is advisable, to minimise the deviation time. When the dose is close to the next scheduled dose or is completely skipped, it is advisable to skip the missed dose and to continue with the regular dosing regimen at the next scheduled time. It is also notable that doubling the dose of rivaroxaban after a missed dose (strategy F) is not recommended based on the drug package insert, the EHRA guide, and our research. In fact, even remedying a half dose (strategy E) is unnecessary. This is inconsistent with the findings of previous similar studies exploring remedial dosing strategies in simulations based on antiepileptic drugs ³²⁻³⁴ or immunosuppressants ³⁷, which are taken every 12 or 24 h. Remedying no extra dose when missing a dose may

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

result in a deviation time that is below the lower limit of the on-therapy range, while remedying a half dose increases the deviation time above the upper limit of the on-therapy range. Furthermore, a double dose substantially increases the drug concentration to levels beyond the upper limit of the on-therapy range. This also leads to a much longer deviation time outside the on-therapy range. The risk of bleeding or thromboembolism varies among patients with atrial fibrillation. The CHA2DS2-VASc (congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke or transient ischaemic attack [TIA], vascular disease, age 65–74 years, sex category) score is commonly used for the assessment of stroke risk ⁴⁰. The risk of stroke may differ for patients of the same age and with the same renal function, considering other factors included in the CHA2DS2-VASc scoring system. Adherence to anticoagulant therapy, such as with rivaroxaban, is particularly important for patients with a high CHA2DS2-VASc score, given their high risk for stroke ³⁸. For example, in patients with a history of bleeding, it is important to avoid an inappropriate remedial strategy. Therefore, deviation times that exceed the upper limit of the on-therapy range and that were below the lower limit of the on-therapy range, representing the risk of bleeding and thromboembolism, respectively, are also listed in Supplementary Tables 3-6. Therefore, clinicians can select the optimal remedial dose for individual patients based on deviation time and patient characteristics.

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

There are several limitations to this study. First, the simulated dosing regimen complied with that of the modelling population, who took 20 or 15 mg daily rivaroxaban based on renal function. Therefore, our recommendations may not apply to patients receiving other doses of rivaroxaban. Second, our recommendations were based on a 90% predicted interval of simulation data. Therefore, attention should be paid to special populations, such extremely obese patients or older patients, who were not included in our analysis. In conclusion, this study assessed the effect of non-adherence to rivaroxaban and explored appropriate remedial dosing regimens for patients with NVAF considering the drug concentration, FXa, and PT. According to our model-informed analysis, the optimal remedial strategy is only dependent on the duration of the delay. We recommend that a rivaroxaban dose is taken following a delay of no more than 6 h, while a half dose may be recommended after 6 h up to a maximum of 4 h before the next dose. No dose is advisable to remedy a missed dose. Clinicians should also balance the risk of bleeding and stroke and select appropriate remedial strategies based on the clinical situation of each patient. Acknowledges We thank Dr. I.G. Girgis from Janssen Pharmaceuticals Research & Development, Raritan, USA for providing details and active discussions on the coding. We thank

Hai-ni Wen MPharm., and Yun-peng Guo MPharm. from Shanghai Chest Hospital for

346

347

348

349

350

351

352

353

354

355

356

357

358

their critical comments. We would also thank Editage (www.editage.cn) for English language editing. **Competing interest** The authors have no conflict of interest to disclose. **Funding** None. **Author contributions** Xiao-qin Liu, Yi-wei Yin, and Zheng Jiao designed the article and planned the work for the manuscript. Xiao-qin Liu, Chen-yu Wang, Zi-ran Li performed the data analysis. Xiao-qin Liu, Yi-wei Yin, Xiao Zhu, and Zheng Jiao drafted and revised the manuscript. All authors approved the finial version of this manuscript.

359	Refe	erence
360	1.	Misselwitz F, Berkowitz SD, Perzborn E. The discovery and development of
361		rivaroxaban. Ann N Y Acad Sci. 2011;1222:64-75.
362	2.	FDA. XARELTO® [insert package]. 2020;
363		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202439s031,02240
364		<u>6s035lbl.pdf</u> .
365	3.	Loo SY, Dell'Aniello S, Huiart L, Renoux C. Trends in the prescription of novel
366		oral anticoagulants in UK primary care. Br J Clin Pharmacol.
367		2017;83(9):2096-2106.
368	4.	Zhu J, Alexander GC, Nazarian S, Segal JB, Wu AW. Trends and Variation in
369		Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017.
370		Pharmacotherapy. 2018;38(9):907-920.
371	5.	Maggioni AP, Dondi L, Andreotti F, et al. Four-year trends in oral anticoagulant
372		use and declining rates of ischemic stroke among 194,030 atrial fibrillation
373		patients drawn from a sample of 12 million people. Am Heart J.
374		2020;220:12-19.
375	6.	Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and
376		pharmacodynamic profile of rivaroxaban. Clinical pharmacokinetics.

2014;53(1):1-16.

377

378	7.	Kvasnicka T, Malikova I, Zenahlikova Z, et al. Rivaroxaban - Metabolism,
379		Pharmacologic Properties and Drug Interactions. Curr Drug Metab.
380		2017;18(7):636-642.
381	8.	Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic
382		embolism with rivaroxaban compared with warfarin in patients with
383		non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J.
384		2011;32(19):2387-2394.
385	9.	Pham PN, Brown JD. Real-world adherence for direct oral anticoagulants in a
386		newly diagnosed atrial fibrillation cohort: does the dosing interval matter? BMC
387		Cardiovasc Disord. 2019;19(1):64.
388	10.	Kim D, Yang PS, Jang E, et al. 10-year nationwide trends of the incidence,
389		prevalence, and adverse outcomes of non-valvular atrial fibrillation nationwide
390		health insurance data covering the entire Korean population. Am Heart J.
391		2018;202:20-26.
392	11.	Weber C, Hung J, Hickling S, et al. Drivers of hospitalisation trends for
393		non-valvular atrial fibrillation in Western Australia, 2000-2013. Int J Cardiol.
394		2019;276:273-277.
395	12.	Rodriguez-Bernal CL, Peiró S, Hurtado I, García-Sempere A, Sanfélix-Gimeno
396		G. Primary Nonadherence to Oral Anticoagulants in Patients with Atrial
397		Fibrillation: Real-World Data from a Population-Based Cohort. J Manag Care
398		Spec Pharm. 2018;24(5):440-448.

399 Reading SR, Black MH, Singer DE, et al. Risk factors for medication 400 non-adherence among atrial fibrillation patients. BMC Cardiovasc Disord. 401 2019;19(1):38-38. 402 14. Moll S, Berkowitz JN, Miars CW. Elite athletes and anticoagulant therapy: an 403 intermittent dosing strategy. Hematology Am Soc Hematol Educ Program. 404 2018;2018(1):412-417. 405 15. Deshpande CG, Kogut S, Laforge R, Willey C. Impact of medication adherence 406 on risk of ischemic stroke, major bleeding and deep vein thrombosis in atrial 407 fibrillation patients using novel oral anticoagulants. Curr Med Res Opin. 408 2018;34(7):1285-1292. 409 Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma 410 concentrations and patient characteristics on the frequency of ischemic stroke 411 and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized 412 Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 413 2014;63(4):321-328. 414 17. Electronic medicines compendium. Xarelto 20/15mg film-coated tablets 415 [Package leaflet: Information for the user]. 2020; 416 https://www.medicines.org.uk/emc/files/pil.2793.pdf. 417 New Zealand Medicines and Medical Devices Safety Authority. 18. 418 XARELTO®[Consumer Medicine Information]. 2020; 419 https://www.medsafe.govt.nz/Consumers/CMI/x/Xarelto.pdf.

420 Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm 421 Association Practical Guide on the use of non-vitamin K antagonist oral 422 anticoagulants in patients with atrial fibrillation. Eur Heart J. 423 2018;39(16):1330-1393. 424 20. Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: 425 considerations on once- vs. twice-daily regimens and their potential impact on 426 medication adherence. Europace. 2015;17(4):514-523. 427 Gu JQ, Guo YP, Jiao Z, Ding JJ, Li GF. How to Handle Delayed or Missed 428 Doses: A Population Pharmacokinetic Perspective. Eur J Drug Metab 429 Pharmacokinet. 2020;45(2):163-172. 430 22. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum 431 creatinine. Nephron. 1976;16(1):31-41. 432 Schmidt M, Ulrichsen SP, Pedersen L, et al. 30-year nationwide trends in 433 incidence of atrial fibrillation in Denmark and associated 5-year risk of heart 434 failure, stroke, and death. Int J Cardiol. 2016;225:30-36. 435 24. Girgis IG, Patel MR, Peters GR, et al. Population pharmacokinetics and 436 pharmacodynamics of rivaroxaban in patients with non-valvular atrial 437 fibrillation: results from ROCKET AF. Journal of clinical pharmacology. 438 2014;54(8):917-927. 439 Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in 25.

nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891.

440

441 Cuker A, Siegal D. Monitoring and reversal of direct oral anticoagulants. 442 Hematology Am Soc Hematol Educ Program. 2015;2015:117-124. 443 27. Samuelson BT, Cuker A. Measurement and reversal of the direct oral 444 anticoagulants. Blood Rev. 2017;31(1):77-84. 445 28. Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: 446 Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American 447 College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 448 2012;141(2 Suppl):e44S-e88S. 449 29. Baglin T, Hillarp A, Tripodi A, et al. Measuring Oral Direct Inhibitors (ODIs) 450 of thrombin and factor Xa: A recommendation from the Subcommittee on 451 Control of Anticoagulation of the Scientific and Standardisation Committee of 452 the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 453 2013;11(4):756-760. 454 Zhang XY, Trame MN, Lesko LJ, Schmidt S. Sobol Sensitivity Analysis: A 30. 455 Tool to Guide the Development and Evaluation of Systems Pharmacology 456 Models. CPT Pharmacometrics Syst Pharmacol. 2015;4(2):69-79. 457 Wang CY, jiao Z, Ding JJ, Yu EQ, Zhu GX. Remedial dosing recommendations 31. 458 for delayed or missed doses of valproic acid in patients with epilepsy based on 459 Monte Carlo simulations. Epilepsy Behav. 2020;111:107265 [Online ahead of 460 print].

461 Yu EQ, Jiao Z, Wang CY, Ding JJ, Zhang XH. Remedial dosing 462 recommendations for delayed or missed doses of lamotrigine in pediatric 463 patients with epilepsy using Monte Carlo simulations. Epilepsy Behav. 464 2019;96:132-140. 465 33. Ding JJ, Zhang YJ, Jiao Z, Wang Y. The effect of poor compliance on the 466 pharmacokinetics of carbamazepine and its epoxide metabolite using Monte 467 Carlo simulation. Acta Pharmacol Sin. 2012;33(11):1431-1440. 468 Dutta S, Reed RC. Effect of delayed and/or missed enteric-coated divalproex 469 doses on valproic acid concentrations: simulation and dose replacement 470 recommendations for the clinician. J Clin Pharm Ther. 2006;31(4):321-329. 471 Magnusson MO, Samtani MN, Plan EL, et al. Dosing and Switching Strategies 472 for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia 473 Based on Population Pharmacokinetic Modeling and Simulation, and Clinical 474 Trial Data. CNS Drugs. 2017;31(4):273-288. 475 Hard ML, Wehr AY, Sadler BM, Mills RJ, von Moltke L. Population 36. 476 Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 477 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole 478 Lauroxil. Eur J Drug Metab Pharmacokinet. 2018;43(4):461-469. 479 Saint-Marcoux F, Woillard JB, Monchaud C, et al. How to handle missed or 37. 480 delayed doses of tacrolimus in renal transplant recipients? A pharmacokinetic 481 investigation. Pharmacol Res. 2015;100:281-287.

38.	Whitlon DS, Sadowski JA, Suttie JW. Mechanism of coumarin action:
	significance of vitamin K epoxide reductase inhibition. Biochemistry.
	1978;17(8):1371-1377.
39.	Siguret V, Abdoul J, Delavenne X, et al. Rivaroxaban pharmacodynamics in
	healthy volunteers evaluated with thrombin generation and the active protein C
	system: Modeling and assessing interindividual variability. Journal of
	Thrombosis and Haemostasis. 2019;17(10):1670-1682.
40.	January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update
	of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With
	Atrial Fibrillation: A Report of the American College of Cardiology/American
	Heart Association Task Force on Clinical Practice Guidelines and the Heart
	Rhythm Society in Collaboration With the Society of Thoracic Surgeons.
	Circulation. 2019;140(2):e125-e151.
	39.

Figure legends

Fig. 1 Simulation scenarios for delayed or missed rivaroxaban doses for patients with non-valvular atrial fibrillation (NVAF) receiving 15 or 20 mg dose every 24 h.

Fig. 2 Graphical representation of six remedial dosing regimens following a delayed or missed dose. Represents an integrated rivaroxaban dose, and represents a half rivaroxaban dose. Patients were assumed to take rivaroxaban at 18:00 daily and to have reached a steady state following a delayed or missed dose.

^a n represents the delayed time, whose range is from 1 to 24 h.

Fig. 3 Percentage of patients with NVAF falling outside the on-therapy ranges *versus* time after the delayed or missed doses in terms of rivaroxaban concentration, FXa activity and PT. (a) Adult patients, 55 years old, CrCl 80 mL/min receiving 20 mg every 24 h (q24h). (b) Adult patients, 55 years old, CrCl 40 mL/min receiving 15 mg q24h. (c) Elderly patients, 75 years old, CrCl 80 mL/min receiving 20 mg q24h. (d) Elderly patients, 75 years old, CrCl 40 mL/min receiving 15 mg q24h. Simulated patients were assumed to take rivaroxaban doses regularly and to have reached steady state.

Fig. 4 Pharmacokinetic (PK) and pharmacodynamic (PD) profiles under full adherence and optimal remedial regimens in terms of rivaroxaban concentration, FXa

activity and PT for elderly patient with CrCl 40 mL/min receiving rivaroxaban 15 mg every 24 h when the dose was delayed for 6 h. (a) Full adherence based on concentration, (b) FXa activity, and (c) PT. (d) optimal remedial regimens in terms of concentration, (e) FXa activity, and (f) PT when the dose was delayed for 6 h. Dark pink shadows represent the distribution of the range between the 5th percentile of the simulated trough concentration (FXa activity or PT) and 95th percentile of the simulated peak concentration (FXa activity or PT). Light pink shadows represent the distribution of the remaining simulated concentration (FXa activity or PT). Red solid lines represent the median of the simulated concentration (FXa activity or PT). The red dotted lines represent the 0.5th percentile and 99.5th percentile of the simulated concentration (FXa activity or PT). Black dotted lines represent the on-therapy range calculated by the simulated concentration (FXa activity or PT). Black horizontal bold solid lines represent the deviation time.

Fig. 5 Total deviation time from recommendations by the European Heart Rhythm Association (EHRA) guide and proposed remedial regimens. (a) Adult patients, 55 years old, CrCl 80 mL/min taking 20 mg every 24 h (q24h). (b) Adult patients, 55 years old, CrCl 40 mL/min taking 15 mg q24h. (c) Elderly patients, 75 years old, CrCl 80 mL/min taking 20 mg q24h. (d) Elderly patients, 75 years old, CrCl 40 mL/min taking 15 mg q24h. Simulated patients were assumed to take rivaroxaban doses regularly and to have reached steady state.

Table

Table 1 Demographic characteristics of simulated patients and corresponding dosing regimens.

ID	Age	BW	LBM ^a	SCr	CrCl ^b	Dose regimen
	(years)	(kg)	(kg)	(mg/dL)	(mL/min)	
1	55	70	55	1.03	80	20 mg q24h
2	55	70	55	2.07	40	15 mg q24h
3	75	70	55	0.79	80	20 mg q24h
4	75	70	55	1.58	40	15 mg q24h

Abbreviations: LBM, lean body mass; BW, body weight; SCr, serum creatinine; CrCl, creatinine clearance.

$$\left(\frac{\text{weight (kg)}}{\text{height (cm)}}\right)^2 \; ; \; \text{for females: LBM (kg)} = 1.07 \cdot \left(\text{weight (kg)}\right) - 148 \cdot \left(\frac{\text{weight (kg)}}{\text{height (cm)}}\right)^2.$$

$$min) = \frac{\left(140 - age(y\,ears)\right) \cdot (weight\,(kg))}{72 \cdot SCr\,(mg/dL)}; \ for \ females: \ CrCl\,(mL/min) = \frac{\left(140 - age(years)\right) \cdot \left(weight\,(kg)\right) \cdot 0.85}{72 \cdot SCr\,(mg/dL)}.$$

^a Calculated lean body mass (LBM) in [kg]. for males: LBM (kg) = $1.10 \cdot (\text{weight (kg)}) - 128 \cdot (\text{weight (kg)})$

^b Calculated creatinine clearance by Cockcroft-Gault formula in [mL/min]. for males: CrCl (mL/

Table 2 Population pharmacokinetic/pharmacodynamic (PK/PD) parameter estimates used in the Monte Carlo simulation ²⁴

PK and P	D parameter (units	s) and	formula	BSV	WSV
				(%)	(%)
PK	$C_{p} = \frac{k_{a} \times F \times}{V \times (k_{a} - k_{a})}$	DOSE - CL V)	$\times \left[\left(\frac{1 - e^{-\frac{CL}{V} \times n \times \tau}}{1 - e^{-\frac{CL}{V} \times \tau}} \times e^{-\frac{CL}{V} \times t} \right) - \left(\frac{1 - e^{-k_a \times n \times \tau}}{1 - e^{-k_a \times \tau}} \right) \right]$	$\times e^{k_a \times t}$	
	$k_{\rm a}$ (/h)	=	1.16	/	47.9
	CL/F (L/h)	=	6.10×(1-0.011×[age-65]	35.2	
			-0.194×[SCr-1.09])		
	V/F (L)	=	79.7×(1-0.00133×[age-65]	17.6	
			+0.0118×[LBM-57.5])		
FXa	$FXa (\%) = E_0$	× (1 -	$-\frac{E_{\text{max}} \times C_{\text{p}}}{EC_{50} + C_{\text{p}}}$		
activity	E_0	=	104% ^a	16.61	10.05
	E_{max}	=	107%	/	
	EC ₅₀ (μg/L)	=	760	5.97	
PT	$PT = PT_0 + slc$	pe×(¬1−exponent×C _p ¬p		
	$PT_0(s)$	=	11.40×(1-0.000192×[CrCl-76])	22.6	12.9
	slope	=	0.0426	/	
	exponent	=	0.0000551×(1+0.0174×[CrCl-76])	4.42	

Abbreviations: PK, pharmacokinetics; k_a , absorption rate constant; CL/F, apparent oral clearance; V/F, volume of distribution; FXa, factor Xa; PT, prothrombin time; BSV, between-subject variability; WSV, within-subject variability.

Notes: data is from Girgis IG, Patel MR, Peters GR, et al. J Clin Pharmacol, 2014, 54 (8): 917-27.

 $^{^{}a}$ E_{0} was reported to be affected by age moderately, but parameter estimate was not shown.

Table 3 Remedial dosing recommendations for patients with atrial fibrillation

Regimen	Delayed	Dose recommendations and strategies ^a based on		
	time (h)	concentration	FXa	PT
20 mg q24h	0-2	20-20 [B/EHRA]	20-20 [B/EHRA]	20-20 [B/EHRA]
(55 years old,	2-3	20-20 [B/EHRA]/	20-20 [B/EHRA]/ 20-20 [B/EHRA]	
CrCl 80		10-20 [C]		10-20 [C]
mL/min)	3-4	10-20 [C]	20-20 [B/EHRA]	10-20 [C]/
				20-20 [B/EHRA]
	4-6	10-20 [C]	20-20 [B/EHRA]	10-20 [C]
	6-7	10-20 [C]	10-20 [C]/20-20 [B]	10-20 [C]
	7-10	10-20 [C]	10-20 [C]	10-20 [C]
	10-12	10-20 [C]	10-20 [C]	10-20 [C]/
				20-10 [D]
	12-14	10-20 [C]/	10-20 [C]	20-10 [D]
		20-10 [D]		
	14-16	10-20 [C]/	10-20 [C]/20-10 [D]	20-10 [D]
		20-10 [D]		
	16-18	20-10 [D]	20-10 [D]	20-10 [D]
	18-20	20-10 [D]	0-20 [A/EHRA]	20-10 [D]
	20-24	0-20 [A/EHRA]	0-20 [A/EHRA]	0-20 [A/EHRA]

Table 3 (continued)

Regimen	Delayed	Dose recommendations and strategie		es ^a based on
	time (h)	concentration	FXa	PT
20 mg q24h	0-2	20-20 [B/EHRA]	20-20 [B/EHRA]	20-20 [B/EHRA]
(75 years old,	2-3	20-20 [B/EHRA]/	20-20 [B/EHRA]	20-20 [B/EHRA]/
CrCl 80		10-20 [C]		10-20 [C]
mL/min)	3-4	10-20 [C]	20-20 [B/EHRA]	10-20 [C]/
				20-20 [B/EHRA]
	4-6	10-20 [C]	20-20 [B/EHRA]	10-20 [C]
	6-10	10-20 [C]	10-20 [C]	10-20 [C]
	10-14	10-20 [C]	10-20 [C]	10-20 [C]/
				20-10 [D]
	14-16	20-10 [D]	10-20 [C]/20-10 [D]	20-10 [D]
	16-18	20-10 [D]	20-10 [D]	20-10 [D]
	18-20	20-10 [D]	20-10 [D]/10-20 [C]/	20-10 [D]
			0-20 [A/EHRA]	
	20-22	0-20 [A/EHRA]	0-20 [A/EHRA]	0-20 [A/EHRA]/
				20-10 [D]
	22-24	0-20 [A/EHRA]	0-20 [A/EHRA]	0-20 [A/EHRA]

Table 3 (continued)

Regimen	Delayed	Dose reco	ommendations and strat	egies ^a based on
	time (h)	concentration	FXa	PT
15 mg q24h	0-2	15-15 [B/EHRA]	15-15 [B/EHRA]	15-15 [B/EHRA]
(55 years old,	2-3	15-15 [B]/	15-15 [B/EHRA]	15-15 [B]/7.5-15 [C]
CrCl 40		7.5-15 [C]		
mL/min)	3-6	7.5-15 [C]	15-15 [B/EHRA]	7.5-15 [C]
	6-8	7.5-15 [C]	15-15 [B/EHRA]/	7.5-15 [C]
			7.5-15 [C]	
	8-10	7.5-15 [C]	7.5-15 [C]	7.5-15 [C]
	10-12	7.5-15 [C]	7.5-15 [C]	7.5-15 [C]/15-7.5 [D]
	12-14	7.5-15 [C]/	7.5-15 [C]	15-7.5 [D]
		15-7.5 [D]		
	14-16	7.5-15 [C]/	7.5-15 [C]/	15-7.5 [D]
		15-7.5 [D]	15-7.5 [D]	
	16-18	15-7.5 [D]	15-7.5 [D]	15-7.5 [D]
	18-20	15-7.5 [D]	15-7.5 [D]/0-15 [A]	15-7.5 [D]
	20-22	0-15 [A/EHRA]	0-15 [A/EHRA]	0-15 [A/EHRA]/
				15-7.5 [D]/7.5-15 [C]/
				22.5-0 [E]
	22-24	0-15 [A/EHRA]	0-15 [A/EHRA]	0-15 [A/EHRA]

Table 3 (continued)

Regimen Delayed Dose recommendation			ommendations and strateg	ries a based on	
	time (h)	concentration	FXa	PT	
15 mg q24h	0-3	15-15 [B/EHRA]	15-15 [B/EHRA]	15-15 [B/EHRA]	
(75 years old,	3-4	15-15 [B/EHRA]/	15-15 [B/EHRA]	7.5-15 [C]/	
CrCl 40		7.5-15 [C]		15-15 [B/EHRA]	
mL/min)	4-5	7.5-15 [C]/	15-15 [B/EHRA]	7.5-15 [C]	
		15-15 [B]			
	5-6	7.5-15 [C]	15-15 [B/EHRA]	7.5-15 [C]	
	7-8	7.5-15 [C]	15-15 [B/EHRA]/	7.5-15 [C]	
			7.5-15 [C]		
	8-12	7.5-15 [C]	7.5-15 [C]	7.5-15 [C]	
	12-14	7.5-15 [C]	7.5-15 [C]	7.5-15 [C]/15-7.5	
				[D]	
	14-16	7.5-15 [C]/	7.5-15 [C]	15-7.5 [D]	
		15-7.5 [D]			
	16-18	15-7.5 [D]	7.5-15 [C]/15-7.5 [D]	15-7.5 [D]	
	18-20	15-7.5 [D]	15-7.5 [D]	15-7.5 [D]	
	20-22	0-15 [A/EHRA]	0-15 [A/EHRA]/	0-15 [A/EHRA]/	
			15-7.5 [D]	15-7.5 [D]/7.5-15	
				[C]	

22-24 0-15 [A/EHRA] 0-15 [A/EHRA] 0-15 [A/EHRA]

Abbreviations: FXa, factor Xa; PT, prothrombin time; CrCl, creatinine clearance. EHRA, European

Heart Rhythm Association

Notes: Simulated patients were assumed to take multiple rivaroxaban doses regularly and have reached

steady state. Six strategies are A) skip the delayed dose, and administrate the regular dose at the next

scheduled time, and then resume the regular dosing regimen; B) administrate a regular dose

immediately, followed by a regular dose at the next scheduled time, and then resume the regular dosing

regimen; C) administrate a half dose immediately followed by a regular dose at the next scheduled time,

and then resume the regular dosing regimen; D) administrate a regular dose immediately followed by a

half dose at the next scheduled time, and then resume the regular dosing regimen; E) administrate one

and a half regular doses immediately and skip a dose at the next scheduled time, and then resume the

regular dosing regimen; F) administrate double doses and skip a dose at the next scheduled time, and


then resume the regular dosing regimen. EHRA guide: administrate the forgotten dose when it's less

than 12 h later; otherwise skipped the dose and took and next scheduled dose.

^a "Dose recommendations" represent "dose taken immediately – dose taken at next schedule time".

39

Strategies with difference in deviation time less than 1 h were considered to be equivalent.



Strategy	Day 1	Day 2	Day 2/3	Day 3	Day 4	Day 5
	18:00	18:00	Delayed <i>n</i> h ^a	18:00	18:00	18:00
	(at steady state)					
А		Missed	Skip			
В		Missed				
С		Missed				
D		Missed				
Е		Missed		Skip		
F		Missed		Skip		

